The Role of miR-21 in HER2-Positive Breast Cancer: A Comprehensive Review of Molecular Mechanisms, Biomarker Potential, and Therapeutic Implications
Keywords:
Breast cancer, HER2, miR-21, Therapeutic resistance, Biomarkers, MetastasisAbstract
Breast cancer continues to be the most prevalent cancer affecting women, with Human Epidermal Growth Factor Receptor 2-positive (HER2-positive) breast cancer presenting particular difficulties because of its aggressive nature and resistance to treatments aimed at specific targets. MicroRNA-21 (miR-21) has been identified as an important factor in controlling HER2-related cancer development, significantly contributing to tumor growth, spread, and resistance to therapy. miR-21 is upregulated by approximately 2-5-fold in HER2-positive tumors compared to HER2-negative tumors, as reported in several clinical studies, correlating with advanced disease stage, lymph node metastasis, and resistance to HER2-targeted therapies. This study explores the multifaceted contributions of miR-21 to HER2-positive breast cancer biology, emphasizing its regulatory role in key oncogenic pathways, including PI3K/AKT/mTOR and MAPK/ERK. Here, discuss the possibility of miR-21 as a biomarker for diagnosis, prognosis, and monitoring therapeutic responses, particularly in liquid biopsy formats such as serum and extracellular vesicles (EVs). Furthermore, this review examines promising therapeutic strategies targeting the miR-21/HER2 axis, highlighting ongoing preclinical developments and future clinical applications. Despite the challenges in standardizing miR-21-based diagnostics and therapies, this review highlights the increasing potential of miR-21 as a therapeutic target, particularly in overcoming resistance to HER2-targeted treatments. This offers a promising pathway toward more personalized and effective options for HER2-positive breast cancer. However, while miR-21 shows significant promise, no therapies targeting miR-21 have been approved for clinical use, emphasizing the need for further research and clinical trials.
Downloads
References
Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review. Cancers. 2021, 13(17), 4287. DOI: 10.3390/cancers13174287
Leon-Ferre RA, Dimitroff K, Yau C, Giridhar KV, Mukhtar R, Hirst G, et al. Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial. Breast Cancer Research. 2025, 27(1), 115. DOI: 10.1186/s13058-025-02070-1
Mercogliano MF, Bruni S, Mauro FL, Schillaci R. Emerging targeted therapies for HER2-positive breast cancer. Cancers. 2023, 15(7), 1987. DOI: 10.3390/cancers15071987
Pan LH, Li JL, Xu Q, Gao ZL, Yang M, Wu XP, et al. HER2/PI3K/AKT pathway in HER2-positive breast cancer: A review. Medicine. 2024, 103(24), e38508. DOI: 10.1097/md.0000000000038508
Cheng XQ. A Comprehensive review of HER2 in cancer biology and therapeutics. Genes. 2024, 15(7), 903. DOI: 10.3390/genes15070903
Pandey S, Yadav P. Exploring the therapeutic potential of microRNAs: targeted gene regulation strategies for enhanced cancer therapy. Journal, Genetic Engineering & Biotechnology. 2025, 23(4), 100556. DOI: 10.1016/j.jgeb.2025.100556
Dan T, Shastri AA, Palagani A, Buraschi S, Neill T, Savage JE, et al. miR-21 plays a dual role in tumor formation and cytotoxic response in breast tumors. Cancers. 2021, 13(4), 888. DOI: 10.3390/cancers13040888
Garrido-Cano I, Pattanayak B, Adam-Artigues A, Lameirinhas A, Torres-Ruiz S, Tormo E, et al. MicroRNAs as a clue to overcome breast cancer treatment resistance. Cancer Metastasis Reviews. 2022, 41(1), 77-105. DOI: 10.1007/s10555-021-09992-0
Amirfallah A, Knutsdottir H, Arason A, Hilmarsdottir B, Johannsson OT, Agnarsson BA, et al. Hsa-miR-21-3p associates with breast cancer patient survival and targets genes in tumor suppressive pathways. PLoS One. 2021, 16(11), e0260327. DOI: 10.1371/journal.pone.0260327
Beňačka R, Szabóová D, Guľašová Z, Hertelyová Z, Radoňák J. Classic and new markers in diagnostics and classification of breast cancer. Cancers. 2022, 14(21), 5444. DOI: 10.3390/cancers14215444
Conte L, Tumolo MR, De Nunzio G, De Giorgi U, Guarino R, Cascio D, et al. The prognostic power of miR-21 in breast cancer: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences. 2025, 26(19), 9713. DOI: 10.3390/ijms26199713
Wang SE, Lin RJ. MicroRNA and HER2-overexpressing cancer. MicroRNA. 2013, 2(2), 137-147. DOI: 10.2174/22115366113029990011
Lee JA, Lee HY, Lee ES, Kim I, Bae JW. Prognostic Implications of MicroRNA-21 Overexpression in invasive ductal carcinomas of the breast. Journal of Breast Cancer. 2011, 14(4), 269-275. DOI: 10.4048/jbc.2011.14.4.269
Richard V, Lee K, Kerin MJ. MicroRNAs as endocrine modulators of breast cancer. International Journal of Molecular Sciences. 2025, 26(7), 3449. DOI: 10.3390/ijms26073449
Shakeri A, Ghanbari M, Tasbandi A, Sahebkar A. Regulation of microRNA-21 expression by natural products in cancer. Phytotherapy Research. 2021, 35(7), 3732-3746. DOI: 10.1002/ptr.7069
Huang TH, Wu FT, Loeb GB, Hsu R, Heidersbach A, Brincat A, et al. Up-regulation of miR-21 by HER2/neu signaling promotes cell invasion. The Journal of Biological Chemistry. 2009, 284(27), 18515-18524. DOI: 10.1074/jbc.M109.006676
Chen ZK, Yuan YC, Wang YZ, Liu Z, Chan HJ, Chen S. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer. Breast Cancer Research and Treatment. 2015, 152(1), 29-39. DOI: 10.1007/s10549-015-3446-8
Newie I, Søkilde R, Persson H, Jacomasso T, Gorbatenko A, Borg Å, et al. HER2-encoded mir-4728 forms a receptor-independent circuit with miR-21-5p through the non-canonical poly(A) polymerase PAPD5. Scientific Reports. 2016, 6, 35664. DOI: 10.1038/srep35664
Mezynski MJ, Farrelly AM, Cremona M, Carr A, Morgan C, Workman J, et al. Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer. Journal of Translational Medicine 2021, 19(1), 184. DOI: 10.1186/s12967-021-02842-1
Kirouac DC, Du J, Lahdenranta J, Onsum MD, Nielsen UB, Schoeberl B, et al. HER2+ cancer cell dependence on PI3K vs. MAPK signaling axes is determined by expression of EGFR, ERBB3 and CDKN1B. PLoS Computational Biology. 2016, 12(4), e1004827. DOI: 10.1371/journal.pcbi.1004827
Das SC, Tasnim W, Rana HK, Acharjee UK, Islam MM, Khatun R. Comprehensive bioinformatics and machine learning analyses for breast cancer staging using TCGA dataset. Briefings in Bioinformatics. 2024, 26(1), bbae628. DOI: 10.1093/bib/bbae628
Pfeffer SR, Yang CH, Pfeffer LM. The role of miR-21 in cancer. Drug Development Research. 2015, 76(6), 270-277. DOI: 10.1002/ddr.21257
De Mattos-Arruda L, Bottai G, Nuciforo PG, Di Tommaso L, Giovannetti E, Peg V, et al. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. Oncotarget. 2015, 6(35), 37269-37280. DOI: 10.18632/oncotarget.5495
Cai Q, Yang HS, Li YC, Zhu J. Dissecting the Roles of PDCD4 in breast cancer. Frontiers in Oncology. 2022, 12, 855807. DOI: 10.3389/fonc.2022.855807
Gong C, Yao YD, Wang Y, Liu BD, Wu W, Chen JN, et al. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. The Journal of Biological Chemistry. 2011, 286(21), 19127-19137. DOI: 10.1074/jbc.M110.216887
Petrovic N, Sami A, Martinovic J, Zaric M, Nakashidze I, Lukic S, et al. TIMP-3 mRNA expression levels positively correlates with levels of miR-21 in in situ BC and negatively in PR positive invasive BC. Pathology, Research and Practice. 2017, 213(10), 1264-1270. DOI: 10.1016/j.prp.2017.08.012
Yu Y, Wang YJ, Ren XB, Tsuyada A, Li A, Liu LJ, et al. Context-dependent bidirectional regulation of the MutS homolog 2 by transforming growth factor β contributes to chemoresistance in breast cancer cells. Molecular Cancer Research. 2010, 8(12), 1633-1642. DOI: 10.1158/1541-7786.Mcr-10-0362
Song B, Wang CX, Liu J, Wang XW, Lv LY, Wei L, et al. MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression. Journal of Experimental & Clinical Cancer Research. 2010, 29(1), 29. DOI: 10.1186/1756-9966-29-29
Ozgün A, Karagoz B, Bilgi O, Tuncel T, Baloglu H, Kandemir EG. MicroRNA-21 as an indicator of aggressive phenotype in breast cancer. Onkologie. 2013, 36(3), 115-118. DOI: 10.1159/000348678
Min WL, Wang BF, Li J, Han J, Zhao Y, Su WJ, et al. The expression and significance of five types of miRNAs in breast cancer. Medical Science Monitor Basic Research 2014, 20, 97-104. DOI: 10.12659/msmbr.891246
Syed RU, Banu H, Alshammrani A, Alshammari MD, G SK, Kadimpati KK, et al. MicroRNA-21 (miR-21) in breast cancer: From apoptosis dysregulation to therapeutic opportunities. Pathology, Research and Practice. 2024, 262, 155572. DOI: 10.1016/j.prp.2024.155572
Bautista-Sánchez D, Arriaga-Canon C, Pedroza-Torres A, De La Rosa-Velázquez IA, González-Barrios R, Contreras-Espinosa L, et al. The Promising Role of miR-21 as a Cancer Biomarker and Its Importance in RNA-Based Therapeutics. Molecular Therapy. Nucleic Acids. 2020, 20, 409-420. DOI: 10.1016/j.omtn.2020.03.003
Subramanian K, Sinha R. Functions of differentially regulated miRNAs in Breast Cancer progression: potential markers for Early detection and candidates for therapy. Biomedicines. 2024, 12(3), 691. DOI: 10.3390/biomedicines12030691
Rhim J, Baek W, Seo Y, Kim JH. From molecular mechanisms to therapeutics: understanding MicroRNA-21 in cancer. Cells. 2022, 11(18), 2791. DOI: 10.3390/cells11182791
Li HP, Liu J, Chen JN, Wang HY, Yang LB, Chen F, et al. A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Nature Communications. 2018, 9(1), 1614. DOI: 10.1038/s41467-018-03537-w
Wang ZZ, Zhou HH, Cheng F, Zhang ZD, Long SH. miR-21 Negatively Regulates the PTEN-PI3K-Akt-mTOR Signaling Pathway in Crohn's Disease by Altering Immune Tolerance and Epithelial-Mesenchymal Transition. Discovery Medicine. 2022, 34(171), 45-58. PMID: 36494326
Zheng LF, Xiang CX, Li XM, Guo QQ, Gao LL, Ni HW, et al. STARD13-correlated ceRNA network-directed inhibition on YAP/TAZ activity suppresses stemness of breast cancer via co-regulating Hippo and Rho-GTPase/F-actin signaling. Journal of Hematology & Oncology. 2018, 11(1), 72. DOI: 10.1186/s13045-018-0613-5
Badr M, Said H, Louka ML, Elghazaly HA, Gaballah A, Atef Abd El Mageed M. MicroRNA-21 as a predictor and prognostic factor for trastuzumab therapy in human epidermal growth factor receptor 2-positive metastatic breast cancer. Journal of Cellular Biochemistry. 2019, 120(3), 3459-3466. DOI: 10.1002/jcb.27620
Liu BQ, Su F, Lv XH, Zhang WB, Shang XC, Zhang YF, et al. Serum microRNA-21 predicted treatment outcome and survival in HER2-positive breast cancer patients receiving neoadjuvant chemotherapy combined with trastuzumab. Cancer Chemotherapy and Pharmacology. 2019, 84(5), 1039-1049. DOI: 10.1007/s00280-019-03937-9
Decker JT, Hall MS, Blaisdell RB, Schwark K, Jeruss JS, Shea LD. Dynamic microRNA activity identifies therapeutic targets in trastuzumab-resistant HER2(+) breast cancer. Biotechnology and Bioengineering. 2018, 115(10), 2613-2623. DOI: 10.1002/bit.26791
Li WT, Zhai LM, Wang H, Liu CL, Zhang JB, Chen WJ, et al. Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer. Oncotarget. 2016, 7(19), 27778-27786. DOI: 10.18632/oncotarget.8413
Wong JS, Cheah YK. Potential miRNAs for miRNA-based therapeutics in breast cancer. Non-coding RNA. 2020, 6(3), 29. DOI: 10.3390/ncrna6030029
Redmond KL, Crawford NT, Farmer H, D'Costa ZC, O'Brien GJ, Buckley NE, et al. T-box 2 represses NDRG1 through an EGR1-dependent mechanism to drive the proliferation of breast cancer cells. Oncogene. 2010, 29(22), 3252-3562. DOI: 10.1038/onc.2010.84
Griñán-Lisón C, Olivares-Urbano MA, Jiménez G, López-Ruiz E, Del Val C, Morata-Tarifa C, et al. miRNAs as radio-response biomarkers for breast cancer stem cells. Molecular Oncology. 2020, 14(3), 556-570. DOI: 10.1002/1878-0261.12635
Haghnavaz N, Asghari F, Elieh Ali Komi D, Shanehbandi D, Baradaran B, Kazemi T. HER2 positivity may confer resistance to therapy with paclitaxel in breast cancer cell lines. Artificial Cells, Nanomedicine, and Biotechnology. 2018, 46(3), 518-523. DOI: 10.1080/21691401.2017.1326927
Liu YH, Xu JS, Choi HH, Han C, Fang YZ, Li YJ, et al. Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer. Nature Communications. 2018, 9(1), 4718. DOI: 10.1038/s41467-018-07264-0
Nielsen BS, Balslev E, Poulsen TS, Nielsen D, Møller T, Mortensen CE, et al. miR-21 expression in cancer cells may not predict resistance to adjuvant trastuzumab in primary breast cancer. Frontiers in Oncology. 2014, 4, 207. DOI: 10.3389/fonc.2014.00207
Yang XW, Wang XM, Shen HY, Deng R, Xue KC. Combination of miR-21 with circulating tumor cells markers improve diagnostic specificity of metastatic breast cancer. Cell Biochemistry and Biophysics. 2015, 73(1), 87-91. DOI: 10.1007/s12013-015-0573-0
Wang M, Ji S, Shao G, Zhang J, Zhao K, Wang Z, et al. Effect of exosome biomarkers for diagnosis and prognosis of breast cancer patients. Clinical & Translational Oncology. 2018, 20(7), 906-911. DOI: 10.1007/s12094-017-1805-0
Omarini C, Catani V, Mastrolia I, Toss A, Banchelli F, Isca C, et al. Extracellular vesicles-derived miR-21 as a biomarker for early diagnosis and tumor activity in breast cancer subtypes. Biomarker Research. 2025, 13(1), 14. DOI: 10.1186/s40364-025-00724-y
Kim MW, Park S, Lee H, Gwak H, Hyun KA, Kim JY, et al. Multi-miRNA panel of tumor-derived extracellular vesicles as promising diagnostic biomarkers of early-stage breast cancer. Cancer Science. 2021, 112(12), 5078-5087. DOI: 10.1111/cas.15155
Venturutti L, Romero LV, Urtreger AJ, Chervo MF, Cordo Russo RI, Mercogliano MF, et al. Stat3 regulates ErbB-2 expression and co-opts ErbB-2 nuclear function to induce miR-21 expression, PDCD4 downregulation and breast cancer metastasis. Oncogene. 2016, 35(17), 2208-2222. DOI: 10.1038/onc.2015.281
Kashyap D, Kaur H. Cell-free miRNAs as non-invasive biomarkers in breast cancer: Significance in early diagnosis and metastasis prediction. Life Sciences. 2020, 246, 117417. DOI: 10.1016/j.lfs.2020.117417
Fan TT, Mao Y, Sun QS, Liu F, Lin JS, Liu YJ, et al. Branched rolling circle amplification method for measuring serum circulating microRNA levels for early breast cancer detection. Cancer Science. 2018, 109(9), 2897-2906. DOI: 10.1111/cas.13725
Pan F, Mao H, Deng L, Li GC, Geng PL. Prognostic and clinicopathological significance of microRNA-21 overexpression in breast cancer: a meta-analysis. International Journal of Clinical and Experimental Pathology. 2014, 7(9), 5622-5633. PMCID: PMC4203174
Müller V, Gade S, Steinbach B, Loibl S, von Minckwitz G, Untch M, et al. Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial. Breast Cancer Research and Treatment. 2014, 147(1), 61-68. DOI: 10.1007/s10549-014-3079-3
Papadaki C, Stoupis G, Tsalikis L, Monastirioti A, Papadaki M, Maliotis N, et al. Circulating miRNAs as a marker of metastatic disease and prognostic factor in metastatic breast cancer. Oncotarget. 2019, 10(9), 966-981. DOI: 10.18632/oncotarget.26629
Tfaily MA, Nassar F, Sellam LS, Amir-Tidadini ZC, Asselah F, Bourouba M, et al. miRNA expression in advanced Algerian breast cancer tissues. PLoS One. 2020, 15(2), e0227928. DOI: 10.1371/journal.pone.0227928
Tsai HP, Huang SF, Li CF, Chien HT, Chen SC. Differential microRNA expression in breast cancer with different onset age. PLoS One. 2018, 13(1), e0191195. DOI: 10.1371/journal.pone.0191195
Jurkovicova D, Smolkova B, Magyerkova M, Sestakova Z, Kajabova VH, Kulcsar L, et al. Down-regulation of traditional oncomiRs in plasma of breast cancer patients. Oncotarget. 2017, 8(44), 77369-77384. DOI: 10.18632/oncotarget.20484
El-Toukhy SE, El-Daly SM, Kamel MM, Nabih HK. The diagnostic significance of circulating miRNAs and metabolite profiling in early prediction of breast cancer in Egyptian women. Journal of Cancer Research and Clinical Oncology. 2023, 149(8), 5437-5451. DOI: 10.1007/s00432-022-04492-2
Jung EJ, Santarpia L, Kim J, Esteva FJ, Moretti E, Buzdar AU, et al. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer. 2012, 118(10), 2603-2614. DOI: 10.1002/cncr.26565
Lee SH, Brianna. Association of microRNA-21 expression with breast cancer subtypes and its potential as an early biomarker. Pathology, Research and Practice. 2024, 254, 155073. DOI: 10.1016/j.prp.2023.155073
Kalinina TS, Kononchuk VV, Yakovleva AK, Alekseenok EY, Sidorov SV, Gulyaeva LF. Association between lymph node status and expression levels of androgen receptor, miR-185, miR-205, and miR-21 in breast cancer subtypes. International Journal of Breast Cancer. 2020, 2020, 3259393. DOI: 10.1155/2020/3259393
Wickramasinghe NS, Manavalan TT, Dougherty SM, Riggs KA, Li Y, Klinge CM. Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells. Nucleic Acids Research. 2009, 37(8), 2584-2595. DOI: 10.1093/nar/gkp117
Singh P, Chaturvedi R, Somvanshi P. Network-based integrative analysis to identify key genes and corresponding reporter biomolecules for triple-negative breast cancer. Cancer Medicine. 2025, 14(9), e70674. DOI: 10.1002/cam4.70674
Radojicic J, Zaravinos A, Vrekoussis T, Kafousi M, Spandidos DA, Stathopoulos EN. MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle. 2011, 10(3), 507-517. DOI: 10.4161/cc.10.3.14754
Yang SF, Li DH. Role of microRNAs in triple‑negative breast cancer and new therapeutic concepts (Review). Oncology Letters. 2024, 28(3), 431. DOI: 10.3892/ol.2024.14565
Savad S, Mehdipour P, Miryounesi M, Shirkoohi R, Fereidooni F, Mansouri F, et al. Expression analysis of MiR-21, MiR-205, and MiR-342 in breast cancer in Iran. Asian Pacific Journal of Cancer Prevention : APJCP. 2012, 13(3), 873-877. DOI: 10.7314/apjcp.2012.13.3.873
Grimaldi AM, Salvatore M, Incoronato M. miRNA-based therapeutics in breast cancer: a systematic review. Frontiers in Oncology. 2021, 11, 668464. DOI: 10.3389/fonc.2021.668464
Qian H, Maghsoudloo M, Kaboli PJ, Babaeizad A, Cui YL, Fu JJ, et al. Decoding the Promise and Challenges of miRNA-Based Cancer Therapies: An Essential Update on miR-21, miR-34, and miR-155. International Journal of Medical Sciences. 2024, 21(14), 2781-2798. DOI: 10.7150/ijms.102123
MacKenzie TA, Schwartz GN, Calderone HM, Graveel CR, Winn ME, Hostetter G, et al. Stromal expression of miR-21 identifies high-risk group in triple-negative breast cancer. The American Journal of Pathology. 2014, 184(12), 3217-3225. DOI: 10.1016/j.ajpath.2014.08.020
Soleimanpour B, Diaz Mochon JJ, Pernagallo S. Amplification-free testing of microRNA biomarkers in cancer. Cancers. 2025, 17(16), 2715. DOI: 10.3390/cancers17162715
Condrat CE, Thompson DC, Barbu MG, Bugnar OL, Boboc A, Cretoiu D, et al. miRNAs as biomarkers in disease: latest findings regarding their role in diagnosis and prognosis. Cells. 2020, 9(2), 276. DOI: 10.3390/cells9020276
Wang H, Peng R, Wang JJ, Qin ZL, Xue LX. Circulating microRNAs as potential cancer biomarkers: the advantage and disadvantage. Clinical Epigenetics. 2018, 10, 59. DOI: 10.1186/s13148-018-0492-1
Katayama ES, Hue JJ, Loftus AW, Ali SA, Graor HJ, Rothermel LD, et al. Stability of microRNAs in serum and plasma reveal promise as a circulating biomarker. Non-coding RNA Research. 2025, 15, 132-141. DOI: 10.1016/j.ncrna.2025.08.001
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Arefeh Zabeti Touchaei
This work is licensed under a Creative Commons Attribution 4.0 International License.
